Real-time optical biopsy and analysis of breast cancer using clinical optical coherence tomography No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2007 ...
Ataxia-telangiectasia (A-T) is a progressive genetic disorder affecting the central nervous and immune systems, and involving chromosomal instability, cancer predisposition, radiation sensitivity and ...
Ataxia-Telangiectasia (AT) is a recessive disorder caused by mutations in the ATM gene, which encodes a serine/threonine kinase central to the cellular response to DNA damage. ATM orchestrates ...
Researchers have found that a protein called ATM (short for ataxia-telangiectasia mutated) can sense the presence of reactive oxygen species and responds by sounding the alarm to trigger the ...
IMMUNOLOGIC abnormalities, including hypogammaglobulinemia, abnormalities of gamma 1 A globulin, poor homograft rejection and structural abnormalities of the thymus gland, have recently been reported ...
CHICAGO — The modified amino acid levacetylleucine (Aqneursa) significantly improved neurologic symptoms and was well tolerated in patients with ataxia-telangiectasia, a rare genetic disorder that ...
IntraBio Inc. today announced that results from its pivotal Phase III clinical trial evaluating levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T) have been published in The Lancet ...
Only successful pivotal Phase III trial in Ataxia-Telangiectasia (A-T), a rare, progressive neurodegenerative disease with no approved treatments Phase III trial successfully achieved its primary ...
"We had previously demonstrated that the p53 gene product--the most commonly mutated gene in human cancer--controls cell-cycle arrest in response to damage," says Kastan. In this paper the authors ...
Ataxia telangiectasia (AT) is a rare genetic condition that people inherit from their parents. AT affects the part of the brain that controls movement and coordination. Ataxia is when a person has ...
AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for levacetylleucine for the ...
Levacetylleucine (Aqneursa) improved neurologic symptoms and functioning in adults and children with ataxia-telangiectasia in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results